Theseus Pharmaceuticals, Inc.
THRX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $12 | $13 | $12 | $10 |
| G&A Expenses | $5 | $5 | $5 | $5 |
| SG&A Expenses | $5 | $5 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16 | $18 | $17 | $15 |
| Operating Income | -$16 | -$18 | -$17 | -$15 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $3 | $2 | $2 |
| Pre-Tax Income | -$14 | -$15 | -$15 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$15 | -$12 | -$15 |
| % Margin | – | – | – | – |
| EPS | -0.31 | -0.34 | -0.29 | -0.4 |
| % Growth | 8.8% | -17.2% | 27.5% | – |
| EPS Diluted | -0.31 | -0.34 | -0.29 | -0.4 |
| Weighted Avg Shares Out | 44 | 44 | 42 | 39 |
| Weighted Avg Shares Out Dil | 44 | 44 | 42 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $0 | $2 |
| Interest Expense | $0 | $0 | $0 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16 | -$18 | -$17 | -$12 |
| % Margin | – | – | – | – |